Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis

Author(s): Alan Valaperti

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 4 , 2016

Become EABM
Become Reviewer
Call for Editor


Myocarditis, which is commonly known as heart inflammation, is a multifaceted disease that includes at least three phases. The host’s immune system is mostly active during the first viral and the second autoimmune phase, when several inflammatory pathways are activated. One of the pivotal transcription factors that regulate immune responses is the nuclear factor kappa B (NF-κB). If, on one side, the acute response to heart injury activates the production of inflammatory cytokines to protect and limit host damage, on the other side sustained and long-term inflammation is one of the leading causes of cardiac hypertrophy and chronic heart failure. An update on the current knowledge of inhibitors and treatments that limit excessive inflammation in experimental and viral autoimmune myocarditis, and therapeutic approaches to cure patients with myocarditis, are described and discussed in this review.

Keywords: Myocarditis, NF-κB p65, cytokines, inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 04 January, 2016
Page: [440 - 449]
Pages: 10
DOI: 10.2174/1381612822666151222160409
Price: $65

Article Metrics

PDF: 39
PRC: 1